Carcinome métaplasique du sein avec différenciation osseuse extensive: À propos d’un cas

Le carcinome métaplasique du sein est une entité rare et bien individualisé par l'OMS. Il représente moins de 1 % des cancers invasifs du sein et constitue un groupe tumoral hétérogène soit purement épithélial soit à doublecontingent épithélial et mésenchymateuse. Le carcinome métaplasique avec différenciation osseuse extensive est très rare. Il représente 0.2% des carcinomes du sein. Nous rapportant un cas exceptionnel d'un carcinome métaplasique du sein avec différenciation osseuse extensive chez une patiente de 53 ans. A travers ce cas et une revue de la littérature, les caractéristiques anatomo-cliniques, radiologique, thérapeutiques et évolutives seront discutées

Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling

Objectives: To compare nilotinib concentrations obtained by venous blood sampling and dried blood spot (DBS) in patients with chronic myeloid leukaemia (CML). It was investigated how to predict nilotinib plasma levels on the basis of DBS. Methods: Forty duplicate DBS and venous blood samples were collected from 20 patients. Capillary blood was obtained by finger prick and spotted on DMPK-C Whatman sampling paper, simultaneously with venous blood sampling. Plasma concentrations were predicted from DBS concentrations using three methods: (1) individual and (2) mean haematocrit correction and (3) the bias between plasma and DBS concentrations. Results were compared using Deming regression and Bland–Altman analysis. Key findings: Nilotinib plasma concentrations ranged from 376 to 2663 μg/l. DBS concentrations ranged from 144 to 1518 μg/l. The slope was 0.56 (95% CI, 0.51 to 0.61) with an intercept of −41.68 μg/l (95% CI, −93.78 to 10.42). Mean differences between calculated and measured plasma concentrations were −14.3% (method 1), −14.0% (method 2) and −0.6% (method 3); differences were within 20% of the mean in 73%, 85% and 80% of the samples, respectively. The slopes were respectively 0.96 (95% CI, 0.86 to 1.06), 0.95 (95% CI, 0.86 to 1.03) and 1.00 (95% CI, 0.91 to 1.09). Conclusions: Plasma concentrations of nilotinib could be predicted on the basis of DBS. DBS sampling to assess nilotinib concentrations in CML patients seems a suitable alternative for venous sampling

Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study

Item does not contain fulltextTo investigate the so-called "drift" with generic-generic drug substitution, a single-dose, four-way crossover comparative bioavailability study was performed involving 24 healthy subjects and three generic and one branded formulation of a tablet containing 800 mg gabapentin as test medication. The results showed that the 90% confidence intervals (CIs) for the area under the drug concentration-time curve (AUC0-t) and for the peak drug concentration (Cmax) were within the acceptance range of 80-125% for all comparisons. The safety profiles of the different gabapentin formulations were comparable. To conclude, all three generic formulations of gabapentin were found to be bioequivalent with the branded formulation and with each other, indicating that the formulations are interchangeable. These results strongly indicate the absence of "drift" with gabapentin generic-generic substitution.Clinical Pharmacology & Therapeutics (2013); 94 4, 519-524. doi:10.1038/clpt.2013.108